Two Prostate Cancer Drugs Delay Spread of the Disease by Two Years

The treatments could help hundreds of thousands of men worldwide stave off pain and chemotherapy, but researchers don ’ t yet know if they will extend lives.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Prostate Cancer Source Type: news

Related Links:

Publication date: Available online 2 June 2018 Source:Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) Author(s): J. Orcajo-Rincon, A.P. Caresia-Aróztegui, M. del Puig Cózar-Santiago, J.R. García-Garzón, M. de Arcocha-Torres, R.C. Delgado-Bolton, M.J. García-Velloso, S. Alvarez-Ruiz, A.M. García-Vicente Bone metastatic disease is the main cause of morbidity/mortality in patients with prostate cancer, presenting frequently as bone pain, pathological fractures or spinal cord compression, which requires early and timely therapy. Although, for the momen...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
Conclusions. This LuPSMA Phase II trial provides evidence of high response rates, pain reduction and low toxicity in men with mCRPC who progressed after conventional therapies. These compelling results indicate the need for randomised trials comparing LuPSMA to existing standard-of-care.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate: Therapy Source Type: research
CONCLUSIONS: The primary site affects patient adjustment to disease. Socioeconomic factors in the area of mental adaptation differentiate colorectal carcinoma patients. PMID: 29704420 [PubMed - in process]
Source: Psychiatria Polska - Category: Psychiatry Tags: Psychiatr Pol Source Type: research
Conclusions: Disease volume is a reliable predictor of survival which should be incorporated with other important factors as; patient performance status and comorbidities in treatment decision-making. PMID: 29699372 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
AbstractPurposeTo gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC).MethodsPatients  ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of lif e, ECOG-performance status, and physicians’ and patients’ perception of health were documented. Reasons for and fact...
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
ch L Abstract PURPOSE: To gain knowledge about the factors associated with discontinuation of scheduled treatment in elderly men with castration-resistant prostate cancer (CRPC). METHODS: Patients ≥ 70 years with CRPC starting a new line of treatment were included in a prospective cohort study. A geriatric assessment (CGA) was performed at baseline, including comorbidity, mobility, functional/mental/nutritional status, as well as depression. Furthermore, pain intensity, quality of life, ECOG-performance status, and physicians' and patients' perception of health were documented. Reasons f...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Cancer Res Clin Oncol Source Type: research
Pain treatment in patients with bone metastasized advanced prostate cancer is often challenging. A range of treatment modalities are available to control prostate cancer-specific pain, such as androgen deprivation therapies, taxane-based chemotherapy, radionuclide therapy with radium-223 or palliative radiotherapy. In addition, analgesics are commonly used for direct symptom management.
Source: Journal of Pain and Symptom Management - Category: Palliative Care Authors: Tags: Letter Source Type: research
ConclusionsRandomized trials testing new drugs as maintenance can be successfully conducted after chemotherapy in castrate-resistant prostate cancer. Maintenance tasquinimod therapy significantly reduced the risk of rPFS by 40%.ClinicalTrialsgov identifier NCT01732549.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Abstract Since November 2013, the alpha emitter radium-223 dichloride (Alpharadin/Xofigo®) has been approved for the treatment of men with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. In the ASYMPCA clinical trial, radium-223 was shown to improve overall survival and to reduce the time to the first symptomatic skeletal event. The use of radium-223 was associated with a reduction of pain and an improvement of health-related quality of life compared to the placebo arm. The efficacy of radium-223 dichloride was not inhibited by the use...
Source: Der Urologe. Ausg. A - Category: Urology & Nephrology Authors: Tags: Urologe A Source Type: research
Conclusions AAP significantly improved outcomes in mCRPC patients compared with prednisone alone regardless of baseline pain and PSA level, and GS at primary diagnosis with no significant differences between observed treatment effects in groups 1 and 2. Patient summary Treatment with abiraterone acetate and prednisone (compared with treatment with prednisone only) for metastatic castration-resistant prostate cancer increased survival in all patients in the study regardless of pain, prostate-specific antigen levels at the start of treatment, and Gleason score at primary diagnosis. This post hoc analysis of the pivotal COU-A...
Source: European Urology - Category: Urology & Nephrology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Pain | Prostate Cancer